Reports

Ideas That Generate Results

List of Figures:

Figure 4-1: Global - Obese Population Aged above 15 Years (Million), 2008 & 2015
Figure 5-1: Global - Obesity Drug Market (Billion US$), 2010-2014
Figure 5-2: Global - Orlistat/Xenical Sales (Million US$), 2008-2010
Figure 5-3: Global - Meridia Sales (Million US$), 2008-2010
Figure 5-4: Global - Acomplia Sales (Million US$), 2007 & 2008
Figure 5-5: Global - Alli Sales (Million GBP), 2008-2010
Figure 6-1: US - Obesity Prevalence (%), 2009 & 2015
Figure 6-2: Mexico - Overweight and Obesity Prevalence (%), 2000 & 2006
Figure 6-3: Canada - Obese Population (Million), 2007-2009
Figure 6-4: Brazil - Obesity Prevalence (%), 2002-03 & 2008-09
Figure 6-5: UK - Obesity Prevalence (%), 2009, 2015 & 2025
Figure 6-6: UK - Obesity Prevalence in Children (%), 2007-08 to 2009-10
Figure 6-7: France - Obesity Prevalence (%), 2003, 2006 & 2009
Figure 6-8: Germany - Overweight and Obesity Prevalence (%), 2008
Figure 6-9: Australia - Obesity Prevalence (%), 2006-07 & 2007-08
Figure 6-10: Australia - Obesity Prevalence in Children Aged 7-15 Years (%), 1985, 1995 & 2007
Figure 6-11: New Zealand - Obesity Prevalence (%), 1997, 2003 & 2007
Figure 6-12: India - Overweight Prevalence (%), 2005 & 2015
Figure 6-13: India - Obesity Drug Market (Billion INR), 2009-2011
Figure 6-14: Qatar - Obesity Prevalence (%), 2003, 2005 & 2010

List of Tables:

Table 3-1: Risk of Co-morbidities based on BMI Levels
Table 6-1: US - Obesity Prevalence by Age Group (%), 2009
Table 6-2: Mexico - Overweight and Obesity Prevalence in Children by Age Group (%), 2006
Table 6-3: Brazil - Obesity Prevalence by Age Group (%), 2008-09
Table 6-4: Australia - Cost of Obesity (Billion US$), 2008-09
Table 6-5: South Africa - Overweight Prevalence in Top Cities (%)
Table 7-1: F Hoffmann-La Roche Ltd - SWOT Analysis
Table 7-2: Abbott Laboratories - SWOT Analysis
Table 7-3: AstraZeneca Plc - SWOT Analysis
Table 7-4: Sanofi-Aventis SA - SWOT Analysis
Table 7-5: Takeda Pharmaceutical Company Limited - SWOT Analysis